7/102 sources · 2 publishersUpdated Oct 14, 22:21 UTC
UBS upgrades Regeneron to Buy and sets $978 price target
On October 14, 2026 UBS raised Regeneron Pharmaceuticals’ rating to Buy, saying the market undervalues its next‑generation Dupixent pipeline. The firm posted a price target of $978, roughly 30% above the recent close of $778.36. UBS also highlighted a GF Value of $923.58 and a GF Score of 87/100, while noting $12.9 million of insider sales over the past year.
Why it matters
The upgrade and higher price target suggest potential upside for investors, as UBS believes the stock is undervalued. Insider selling of $12.9 million may temper enthusiasm, but the strong valuation metrics provide a margin of safety.
Key facts
- 1UBS upgraded Regeneron to a Buy rating on October 14, 2026. gurufocus.com
- 2UBS set a price target of $978, implying roughly 30% upside from the recent closing price of $778.36. gurufocus.com
- 3GuruFocus GF Value™ for Regeneron is $923.58, indicating a 15.7% margin of safety versus the current price of $778.36. gurufocus.com
- 4Regeneron’s GF Score™ is 87 out of 100. gurufocus.com
- 5Insiders have sold $12.9 million of Regeneron shares over the past 12 months with no insider purchases. gurufocus.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.